Neal Fowler, Pathalys Pharma CEO
August 20, 2024 09:50 AM EDT
Financing
Startups

TCGX and JPM help Pathalys raise $105M to go up against Am­gen in sub­set of kid­ney dis­ease

Kyle LaHucik

Senior Reporter

North Car­oli­na biotech Pathalys Phar­ma ex­pects to do a rare thing with its nine-fig­ure Se­ries B: file for FDA ap­proval. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3

Cigna sues FTC, call­ing for with­draw­al of 'bi­ased, er­ro­neous' PBM re­port

23andMe heads to ES­MO to tout its two clin­i­cal-stage drugs af­ter scrap­ping dis­cov­ery team

Mer­ck and Dai­ichi’s re­ject­ed HER3 ADC clears a Phase 3 in cer­tain lung can­cers

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times